Table 3.

Cases of anaemia observed with nivolumab in the literature

Case report	No. of cycles before anaemia	Nivolumab dose	Type of anaemia	Primary malignancy	Mediator IgG or C3	Treatment of AIHA	Immunotherapy re-challenge
Yuki et al11	31 cycles	Nivolumab 2 mg/kg every 6 weeks	PRA (pure red cell aplasia)	Melanoma	None	High- dose steroids	Yes, without recurrence of anaemia
Khan et al7	2 cycles	Nivolumab and ipilimumab	AIHA	Melanoma	Unknown	High-dose steroids, rituximab	Yes, with recurrence of anaemia
Tardy et al9	2 cycles	Nivolumab 3 mg/kg	AIHA	Hodgkin lymphoma	IgG	High-dose steroids	Yes, without recurrence of anaemia
Schwab et al10	8 cycles	Nivolumab 3 mg/kg every 2 weeks	AIHA	Squamous cell skin cancer	IgG, C3	High-dose steroids	No
Palla et al8	2 cycles	Nivolumab 3 mg/kg every 2 weeks	AIHA	Metastatic lung cancer	C3	High-dose steroids	No; patient died
Kong et al6	4 cycles	Nivolumab	AIHA	Metastatic melanoma	IgG	High-dose steroids	No

AIHA, autoimmune haemolytic anaemia; Ig, imuunoglobulin.